Yervoy Intravenous infusion 20mg, manufactured by Bristol-Myers Squibb, contains Ipilimumab (genetical recombination), a CTLA-4-blocking antibody. It is indicated for unresectable or metastatic melanoma, adjuvant treatment of melanoma, advanced renal cell carcinoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer. This 20mg 4mL bottle has a YJ code of 4291430A2022.
Yervoy Intravenous infusion 20mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →